Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancers With HER2 Expression”

116 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 116 results

Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Not applicableLooking for participantsNCT06909604
What this trial is testing

Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Peking University Cancer Hospital & Institute 50
Testing effectiveness (Phase 2)UnknownNCT06178601
What this trial is testing

RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Shanxi Province Cancer Hospital 36
Testing effectiveness (Phase 2)Ended earlyNCT04168931
What this trial is testing

Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

Who this might be right for
Gastric Cancer Stage IV
AC Camargo Cancer Center 5
Not applicableUnknownNCT02843412
What this trial is testing

The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry

Who this might be right for
Gastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks
Shanghai Zhongshan Hospital 2,000
Testing effectiveness (Phase 2)UnknownNCT04826107
What this trial is testing

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 196
Early research (Phase 1)Study completedNCT02073916
What this trial is testing

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jenny C. Chang, MD 24
Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 26
Testing effectiveness (Phase 2)Looking for participantsNCT06413745
What this trial is testing

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Who this might be right for
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd. 65
Testing effectiveness (Phase 2)Study completedNCT00944047
What this trial is testing

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Who this might be right for
Breast Cancer
University of Kansas Medical Center 32
Early research (Phase 1)Looking for participantsNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)Looking for participantsNCT06063018
What this trial is testing

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Who this might be right for
Cervical Cancer Recurrent
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Not applicableLooking for participantsNCT07376174
What this trial is testing

The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy

Who this might be right for
Breast CancerHER2/CEP17 Ratio
Shandong Cancer Hospital and Institute 300
Not applicableLooking for participantsNCT07030569
What this trial is testing

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Who this might be right for
RadiomicRadiomicsBreast Cancer Metastatic+13 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 500
Early research (Phase 1)Study completedNCT01730118
What this trial is testing

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Who this might be right for
Breast NeoplasmsBreast CancerAdenocarcinomas+1 more
National Cancer Institute (NCI) 33
Testing effectiveness (Phase 2)Looking for participantsNCT06378242
What this trial is testing

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)Ended earlyNCT01531764
What this trial is testing

BIBW 2992 (Afatinib) and Vinorelbine

Who this might be right for
Carcinoma Breast Stage IV
University of Magdeburg 2
Early research (Phase 1)Looking for participantsNCT05872295
What this trial is testing

IKS014 in Advanced Solid Tumors That Express HER2

Who this might be right for
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd. 165
Load More Results